XavTrap is a recombinant platform technology using yeast cell fragments to rapidly express single-chain variable fragment (scFV), nanobodies or peptides for diagnostic applications.
This platform technology can be rapidly made to target a specific disease (Disease X), including seasonal mutations of influenzas and coronavirus.
Xing XavTrap® platform produces lead candidates 66% faster than cutting edge mammalian antibody pipelines, which XING has validated as part of the NIH-RADx Program*.